303 related articles for article (PubMed ID: 35045482)
21. A case of conversion hepatectomy for huge hepatocellular carcinoma with adrenal metastasis and vascular invasion after atezolizumab-bevacizumab treatment.
Hoshino T; Naganuma A; Furusawa A; Suzuki Y; Hirai K; Sakamoto I; Ogawa T; Ogawa A; Hatanaka T; Kakizaki S
Clin J Gastroenterol; 2022 Aug; 15(4):776-783. PubMed ID: 35585285
[TBL] [Abstract][Full Text] [Related]
22. Two cases of hepatocellular carcinoma successfully treated by carbon ion radiotherapy after atezolizumab plus bevacizumab treatment.
Takakusagi S; Tanaka H; Naganuma A; Kakizaki S; Shibuya K; Ohno T; Takagi H; Uraoka T
Clin J Gastroenterol; 2023 Jun; 16(3):407-415. PubMed ID: 36750524
[TBL] [Abstract][Full Text] [Related]
23. Conversion Surgery After Atezolizumab Plus Bevacizumab for Primary and Peritoneal Metastasis After Hepatocellular Carcinoma Rupture.
Miyata T; Sugi K; Horino T; Ono A; Tagayasu Y; Nomoto D; Inoue M; Mizumoto T; Kubota T; Yanagida E; Murayama T; Miyanari N; Baba H
Anticancer Res; 2023 Feb; 43(2):943-947. PubMed ID: 36697062
[TBL] [Abstract][Full Text] [Related]
24. Organ-specific response with first-line atezolizumab-bevacizumab versus lenvatinib for patients with advanced hepatocellular carcinoma.
Kim HD; Park YG; Kim S; Kim KP; Park SR; Ryu MH; Ryoo BY; Yoo C
Hepatol Int; 2024 Jun; 18(3):973-983. PubMed ID: 38214792
[TBL] [Abstract][Full Text] [Related]
25. Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab.
Kikuchi T; Takeuchi Y; Nouso K; Kariyama K; Kuwaki K; Toshimori J; Iwado S; Moriya A; Hagihara H; Takabatake H; Tada T; Yasunaka T; Sakata M; Sue M; Miyake N; Adachi T; Wada N; Onishi H; Shiraha H; Takaki A; Otsuka M
Liver Int; 2024 Jun; 44(6):1456-1463. PubMed ID: 38488749
[TBL] [Abstract][Full Text] [Related]
26. Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states.
Wen F; Zheng H; Zhang P; Liao W; Zhou K; Li Q
Liver Int; 2021 May; 41(5):1097-1104. PubMed ID: 33556230
[TBL] [Abstract][Full Text] [Related]
27. Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol.
Ben Khaled N; Seidensticker M; Ricke J; Mayerle J; Oehrle B; Rössler D; Teupser D; Ehmer U; Bitzer M; Waldschmidt D; Fuchs M; Reuken PA; Lange CM; Wege H; Kandulski A; Dechêne A; Venerito M; Berres ML; Luedde T; Kubisch I; Reiter FP; De Toni EN
Future Oncol; 2022 Apr; 18(12):1423-1435. PubMed ID: 35081747
[TBL] [Abstract][Full Text] [Related]
28. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Finn RS; Qin S; Ikeda M; Galle PR; Ducreux M; Kim TY; Kudo M; Breder V; Merle P; Kaseb AO; Li D; Verret W; Xu DZ; Hernandez S; Liu J; Huang C; Mulla S; Wang Y; Lim HY; Zhu AX; Cheng AL;
N Engl J Med; 2020 May; 382(20):1894-1905. PubMed ID: 32402160
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of atezolizumab plus bevacizumab combination therapy in patients with unresectable hepatocellular carcinoma undergoing dialysis: a case series.
Sakaguchi K; Satoh T; Kawaguchi S; Aoyama T; Asahara K; Endo S; Shirane N; Kanemoto H; Oba N; Ohno K
Clin J Gastroenterol; 2024 Jun; 17(3):515-522. PubMed ID: 38502472
[TBL] [Abstract][Full Text] [Related]
30. Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma.
D'Alessio A; Cammarota A; Zanuso V; Pressiani T; Personeni N; Rimassa L
Expert Rev Anticancer Ther; 2021 Sep; 21(9):927-939. PubMed ID: 34167423
[No Abstract] [Full Text] [Related]
31. Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience.
Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y; Kudo M;
Cancer Rep (Hoboken); 2022 Feb; 5(2):e1464. PubMed ID: 34114752
[TBL] [Abstract][Full Text] [Related]
32. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real-world cohort.
Jost-Brinkmann F; Demir M; Wree A; Luedde T; Loosen SH; Müller T; Tacke F; Roderburg C; Mohr R
Aliment Pharmacol Ther; 2023 Jun; 57(11):1313-1325. PubMed ID: 36883351
[TBL] [Abstract][Full Text] [Related]
33. Pathologic Complete Response after Chemotherapy with Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma with Tumor Thrombus in the Main Portal Trunk.
Kurisaki K; Soyama A; Hara T; Matsushima H; Imamura H; Tanaka T; Adachi T; Ito S; Kanetaka K; Hidaka M; Okano S; Eguchi S
Dig Surg; 2023; 40(1-2):84-89. PubMed ID: 36848877
[TBL] [Abstract][Full Text] [Related]
34. Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study.
Sugimoto R; Satoh T; Ueda A; Senju T; Tanaka Y; Yamashita S; Koyanagi T; Kurashige T; Higuchi N; Nakamura T; Tanaka M; Azuma Y; Ohno A; Ooho A; Ooe M; Mutsuki T; Uchimura K; Kuniyoshi M; Tada S; Aratake Y; Yoshimoto T; Yamashita N; Harada S; Nakamuta M; Motomura K; Kohjima M;
Medicine (Baltimore); 2022 Oct; 101(40):e30871. PubMed ID: 36221372
[TBL] [Abstract][Full Text] [Related]
35. Treatment of hepatocellular carcinoma with a portal vein tumor thrombus and pulmonary metastases of rectal cancer with microsatellite stability using atezolizumab plus bevacizumab.
Inaba Y; Chatani S; Murata S; Sato Y; Imamine R; Kato M; Onaya H; Yamaura H
Clin J Gastroenterol; 2024 Apr; 17(2):286-291. PubMed ID: 38341819
[TBL] [Abstract][Full Text] [Related]
36. Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: Case report and literature review.
Özdirik B; Jost-Brinkmann F; Savic LJ; Mohr R; Tacke F; Ploner CJ; Roderburg C; Müller T
Medicine (Baltimore); 2021 Jun; 100(24):e26377. PubMed ID: 34128898
[TBL] [Abstract][Full Text] [Related]
37. Atezolizumab plus bevacizumab as a downstaging therapy for liver transplantation in hepatocellular carcinoma with portal vein thrombosis: The first report.
Kumar P; Krishna P; Nidoni R; Adarsh CK; Arun MG; Shetty A; Mathangi J; Sandhya ; Gopasetty M; Venugopal B
Am J Transplant; 2024 Jun; 24(6):1087-1090. PubMed ID: 38219868
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma.
Xin Y; Cao F; Yang H; Zhang X; Chen Y; Cao X; Zhou X; Li X; Zhou J
Front Immunol; 2022; 13():929141. PubMed ID: 35990634
[TBL] [Abstract][Full Text] [Related]
39. Synchronous Primary Lung Adenocarcinoma and Hepatocellular Carcinoma Successfully Treated with a Combination of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel.
Egawa T; Masuzawa K; Nakayama S; Maeda I; Tsunematsu S; Suzuki Y; Suzuki Y
Intern Med; 2021 Oct; 60(20):3273-3277. PubMed ID: 33840693
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study.
Persano M; Rimini M; Tada T; Suda G; Shimose S; Kudo M; Cheon J; Finkelmeier F; Lim HY; Rimassa L; Presa J; Masi G; Yoo C; Lonardi S; Tovoli F; Kumada T; Sakamoto N; Iwamoto H; Aoki T; Chon HJ; Himmelsbach V; Pressiani T; Kawaguchi T; Montes M; Vivaldi C; Soldà C; Piscaglia F; Hiraoka A; Sho T; Niizeki T; Nishida N; Steup C; Iavarone M; Di Costanzo G; Marra F; Scartozzi M; Tamburini E; Cabibbo G; Foschi FG; Silletta M; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Cammarota A; Burgio V; Cascinu S; Casadei-Gardini A
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5591-5602. PubMed ID: 36509984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
